Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on intranasal drug delivery for emergency medical conditions[1] - The company's proprietary Nasax® technology aims to enhance intranasal drug absorption and potentially offer longer shelf-life[6, 4] - Nasus has strong IP protection extending to 2038[6] NS002 (Intranasal Epinephrine) - NS002 is in Phase 2 development for anaphylaxis and has demonstrated faster epinephrine absorption compared to EpiPen in studies[7] - A pilot study showed NS002 epinephrine absorbed into the bloodstream faster than EpiPen[37] - Phase 2 study results showed that 91% of patients reached the clinical threshold of 100pg/mL at 6 minutes with NS002 4mg, compared to 55% with EpiPen[53] - NS002 4mg achieved a mean Cmax of 477 pg/mL, while EpiPen achieved 360 pg/mL[63] - NS002 4mg achieved a median Tmax of 10 minutes, while EpiPen achieved 15 minutes[63] Market Opportunity - The global epinephrine market was approximately $2.3 billion in 2024[34] - Anaphylaxis affects an estimated 1-3% of the global population[33]